Phase 3 Readout~month

Phase 3 Topline: An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Trea

Indication
Fabry Disease

Other upcoming events for FOLD

Phase 3 ReadoutPhase 3 Topline: An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects With F
Phase 3 ReadoutPhase 3 Topline: An Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, Pharmacodynamics, and Immuno
Patent ExpiryPatent/Exclusivity Expiry: STEGLATRO
Patent ExpiryPatent/Exclusivity Expiry: SEGLUROMET
Patent ExpiryPatent/Exclusivity Expiry: STEGLUJAN

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12 Month Trea — FOLD Phase 3 Readout | BioSniper